Can Early B-Type Natriuretic Peptide Assays Predict Symptomatic Patent Ductus Arteriosus in Extremely Low Birth Weight Infants?
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jang Hoon | - |
dc.contributor.author | Shin, Jeong Hee | - |
dc.contributor.author | Park, Kyu Hee | - |
dc.contributor.author | Rhie, Young Jun | - |
dc.contributor.author | Park, Moon Sung | - |
dc.contributor.author | Choi, Byung Min | - |
dc.date.accessioned | 2021-09-06T11:30:28Z | - |
dc.date.available | 2021-09-06T11:30:28Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 1661-7800 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/106519 | - |
dc.description.abstract | Background: Earlier and more accurate identification of a high-risk group of preterm infants that are likely to develop a hemodynamically significant patent ductus arteriosus (hsPDA) would allow specific targeting of early treatment and thus possibly minimize the morbidity and mortality associated with a PDA in extremely low birth weight (ELBW) infants. Objective: To investigate the predictability of B-type natriuretic peptide (BNP) for early targeted treatment of hsPDA in ELBW infants. Methods: 73 ELBW infants that underwent echocardiographic evaluation and plasma BNP measurement after birth were enrolled. 31 infants developed hsPDA (HsPDA group) and 42 infants did not develop hsPDA (nPDA group). Results: BNP levels of the HsPDA group were significantly higher than those of the nPDA group at 24 h of age (921 [318-2,133] vs. 152 [91-450] pg/ml) but not different at 12 h of age. BNP levels at 24 h of age were significantly correlated with the magnitudes of the ductal shunt but not at 12 h of age. The area under the receiver operator characteristic curve of BNP levels for prediction of hsPDA at 24 h of age was 0.830. At the cutoff BNP levels of 200 and 900 pg/ml at 24 h of age, sensitivity was 83.9 and 54.8% and specificity was 61.9 and 95.2%, respectively. Conclusions: BNP levels at 24 h of age can be used as a guide for early targeted treatment of hsPDA and avoid the unnecessary use of cyclooxygenase inhibitors in ELBW infants. Copyright (C) 2012 S. Karger AG, Basel | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KARGER | - |
dc.subject | PRETERM INFANTS | - |
dc.subject | NT-PROBNP | - |
dc.subject | DISEASE | - |
dc.subject | BNP | - |
dc.title | Can Early B-Type Natriuretic Peptide Assays Predict Symptomatic Patent Ductus Arteriosus in Extremely Low Birth Weight Infants? | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Rhie, Young Jun | - |
dc.contributor.affiliatedAuthor | Choi, Byung Min | - |
dc.identifier.doi | 10.1159/000343034 | - |
dc.identifier.scopusid | 2-s2.0-84869867073 | - |
dc.identifier.wosid | 000312443700007 | - |
dc.identifier.bibliographicCitation | NEONATOLOGY, v.103, no.2, pp.118 - 122 | - |
dc.relation.isPartOf | NEONATOLOGY | - |
dc.citation.title | NEONATOLOGY | - |
dc.citation.volume | 103 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 118 | - |
dc.citation.endPage | 122 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pediatrics | - |
dc.relation.journalWebOfScienceCategory | Pediatrics | - |
dc.subject.keywordPlus | PRETERM INFANTS | - |
dc.subject.keywordPlus | NT-PROBNP | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | BNP | - |
dc.subject.keywordAuthor | B-type natriuretic peptide | - |
dc.subject.keywordAuthor | Patent ductus arteriosus | - |
dc.subject.keywordAuthor | Preterm infant | - |
dc.subject.keywordAuthor | Predictable usefulness | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.